Cat. No.
MABL-3785
Application
IHC (P), WB
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
HL1925
From
Recombinant Antibody
Specificity
This antibody binds human CIP2A (cancerous inhibitor of protein phosphatase 2A). CIP2A is an oncoprotein that inhibits protein phosphatase 2A (PP2A), stabilizes MYC, and is involved in the progression of several human malignancies. It promotes anchorage-independent cell growth and tumor formation.Antibodies against CIP2A are present in sera from many patients with gastric or prostate cancer and acts as prognostic marker in many cancers.
Alternative Names
Cancerous inhibitor of protein phosphatase 2A; Cancerous inhibitor of PP2A; Protein CIP2A; p90 autoantigen; KIAA1524
UniProt
Q8TCG1
Immunogen
The original antibody was generated by immunizing mice with C-terminal CIP2A as an immunogen.
Application Notes
This antibody can be used for the immunohistochemical staining of CIP2a expressed on the surface of prostate cancer, benign prostatic hyperplasia and high grade prostatic intraepithelial neoplasia tissues (PMID:32860375). This antibody can be for the identification of CIP2a protein from cell lysates using western blot (PMID: 31031016).
Antibody First Published
Note on publication
Size
266 μg Purified antibody.
Concentration
167 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 466.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 186⁰C.
![Anti-VEGF [Bevacizumab] (MABL-](/public/static/common/images/not_adv.jpg)
